TCGA-56-7579-01A-11R-2045-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 61
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.570
- G2M_CHECKPOINT+0.480
- E2F_TARGETS+0.470
- MYC_TARGETS_V1+0.440
- UNFOLDED_PROTEIN_RESPONSE+0.300
- MTORC1_SIGNALING+0.270
- MITOTIC_SPINDLE+0.260
- OXIDATIVE_PHOSPHORYLATION+0.260
- DNA_REPAIR+0.220
- NOTCH_SIGNALING+0.190
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.390
- INTERFERON_ALPHA_RESPONSE-0.380
- IL6_JAK_STAT3_SIGNALING-0.330
- INTERFERON_GAMMA_RESPONSE-0.320
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.280
- HYPOXIA-0.250
- UV_RESPONSE_DN-0.220
- IL2_STAT5_SIGNALING-0.190
- TNFA_SIGNALING_VIA_NFKB-0.180
- MYOGENESIS-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | s0094236 | — | — | 0.870 |
| 2 | TCGA-DQ-7588-01A-11R-2081-07 | — | — | 0.869 |
| 3 | e235012b-4b29-478a-abad-6a70cd949cfa | — | — | 0.867 |
| 4 | MNG1063 | — | — | 0.862 |
| 5 | ERR2208894 | — | — | 0.858 |
| 6 | TCGA-94-8035-01A-11R-2247-07 | — | cohortSQ1 | 0.857 |
| 7 | SRR8392895 | — | cohortSQ2 | 0.857 |
| 8 | TCGA-MF-A522-01A-11R-A262-07 | — | cohortSQ2 | 0.855 |
| 9 | SRR8613799 | — | E | 0.854 |
| 10 | BS_MV6ASWV9 | ATRT | — | 0.852 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.570 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.480 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.470 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.440 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.270 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.260 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.260 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.220 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.190 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.160 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.140 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.130 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.120 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.090 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.080 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.070 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.070 | Idelalisib | — uncovered |